DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma

Annals of Oncology

Volumn 25, Issue 5, 2014, Pages 968-974

  Gupta, A ^a   Love, S ^b   Schuh, A ^a   Shanyinde, M ^b   Larkin, J M ^c   Plummer, R ^d   Nathan, P D ^e   Danson, S ^f   Ottensmeier, C H ^g   Lorigan, P ^h   Collins, L ⁱ   Wise, A ⁱ   Asher, R ^a   Lisle, R ^b   Middleton, M R ^a,j  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e MOUNT VERNON CANCER CENTRE   (United Kingdom)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

^g UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^h CHRISTIE HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

more..

Author keywords

BRAF; MEK; Melanoma; Phase II; Selumetinib; Trial

Indexed keywords

B RAF KINASE; DOCETAXEL; PLACEBO; SELUMETINIB; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; TAXOID;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; BRAF GENE; CANCER COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTATIC MELANOMA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; ONCOGENE N RAS; OVERALL SURVIVAL; PAIN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; TREATMENT OUTCOME; VISUAL DISORDER; VOMITING; WILD TYPE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SECONDARY; SKIN NEOPLASMS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DOUBLE-BLIND METHOD; GTP PHOSPHOHYDROLASES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 84905987840     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu054     Document Type: Article

References (21)

1. International Agency for Research on Cancer. GLOBOCON 2008; http://globocan. iarc.fr/ (31 March 2013, date last accessed).
2. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 2009; 23(6): 488-496.
3. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366(26): 2443-2454.
4. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367(18): 1694-1703.
5. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369(2): 122-133.
6. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003; 104(5): 527-532.
7. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364(26): 2507-2516.
8. Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380(9839): 358-365.
9. Haass NK, Sproesser K, Nguyen TK et al. The mitogen-activated protein/ extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008; 14(1): 230-239.
10. Adjei AA, Cohen RB, Franklin W et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008; 26(13): 2139-2146.
11. Kirkwood JM, Bastholt L, Robert C et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012; 18(2): 555-567.
12. Robert C, Dummer R, Gutzmer R et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol 2013; 14(8): 733-740.
13. Bedikian AY, Weiss GR, Legha SS et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol 1995; 13(12): 2895-2899.
14. Mhaidat NM, Wang Y, Kiejda KA et al. Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2. Mol Cancer Ther 2007; 6(2): 752-761.
15. Mhaidat NM, Zhang XD, Jiang CC et al. Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res 2007; 13(4): 1308-1314.
16. Holt SV, Logie A, Odedra R et al. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Br J Cancer 2012; 106(5): 858-866.
17. Kim K, Infante J, Cohen R et al. A phase 1 dose-escalation study of selumetinib in combination with docetaxel in patients with advanced solid tumours. Mol Cancer Ther 2011; 10(11): abstract B225.
18. Janne PA, Shaw AT, Pereira JR et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebocontrolled, phase 2 study. Lancet Oncol 2013; 14(1): 38-47.
19. Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367(2): 107-114.
20. Ascierto PA, Schadendorf D, Berking C et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, openlabel phase 2 study. Lancet Oncol 2013; 14(3): 249-256.
21. Jakob JA, Bassett RL, Jr, Ng CS et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012; 118(16): 4014-4023.